Key result
Three doses of BNT162b2 or CoronaVac elicited comparable seroconversion against wild-type SARS-CoV-2 in neuromuscular disease patients compared to healthy controls, maintaining durability at 6 months.
Why the study?
The durability of immunogenicity elicited by three doses of BNT162b2 and CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs, has not been well-established.
Do 3 doses of BNT162b2 or CoronaVac elicit durable humoral immunogenicity in patients with neuromuscular diseases compared to healthy controls?
Observational
Do 3 doses of BNT162b2 or CoronaVac elicit durable humoral immunogenicity in patients with neuromuscular diseases compared to healthy controls?
Three doses of BNT162b2 or CoronaVac elicit durable humoral immunogenicity in patients with neuromuscular diseases, including those on corticosteroids, comparable to healthy controls.
Supports three-dose regimens in neuromuscular disease patients; leaves open variant-specific protection and clinical outcomes.
The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-term humoral immunogenicity outcomes after 3 doses of these vaccines. Peripheral blood samples were collected from participants 14-49 days and 155-210 days after administration of the third vaccine dose to assess humoral immune responses through serological assays. The immunogenicity outcomes of each patient were compared to those of three age-matched healthy control participants, ensuring a balanced comparison. Both patients that received 3 doses of BNT162b2 and 10 (90.9%) patients that received CoronaVac seroconverted against wild-type-SARS-CoV-2 virus, showing comparable antibody responses to healthy participants. After 6 months, one patient in BNT162b2 and all four patients in CoronaVac groups maintained seropositivity. The JN-1 specific binding antibody response was lower compared to wild-type virus. The use of corticosteroids did not affect seroconversion rate against wild-type virus or JN.1 variant. BNT162b2 and CoronaVac were immunogenic for neuromuscular diseases patients, maintaining durability after 6 months even for those on corticosteroids. Our data support a rapid immunization series utilizing mRNA-based and whole-virus inactivated vaccines for future pandemic.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2024) conducted an observational in Neuromuscular diseases. BNT162b2 or CoronaVac vs. Age-matched healthy controls was evaluated on Seroconversion against wild-type-SARS-CoV-2 virus. Three doses of BNT162b2 or CoronaVac elicited comparable seroconversion against wild-type SARS-CoV-2 in neuromuscular disease patients compared to healthy controls, maintaining durability at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: